The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sulfonylurea     aminocarbonylsulfamoylurea

Synonyms: AG-F-22963, CHEBI:26831, AC1Q5QER, CTK4H4686, AR-1L8037, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of aminocarbonylsulfamoylurea


Psychiatry related information on aminocarbonylsulfamoylurea


High impact information on aminocarbonylsulfamoylurea


Chemical compound and disease context of aminocarbonylsulfamoylurea


Biological context of aminocarbonylsulfamoylurea

  • Intracellular application of the sulfonylurea tolbutamide during whole-cell patch-clamp recordings stimulated exocytosis >5-fold when applied at a cytoplasmic Ca2+ concentration of 0.17 microM [21].
  • Our results also show that mutations in the slide helix of Kir6.2 (V59G) influence the channel kinetics, providing evidence that this domain is involved in Kir channel gating, and suggest that the efficacy of sulfonylurea therapy in PNDM may vary with genotype [22].
  • Our results confirm that the M(r) 140,000 polypeptide contains the beta-cell high affinity glyburide binding site and show that the second generation sulfonylurea antidiabetic drugs have a selective increase in affinity for this receptor [23].
  • Exposure of human islets for 4 days to 11.1 and 33.3 mmol/l glucose, 2 ng/ml IL-1beta, or 10 and 100 micromol/l of the sulfonylurea tolbutamide induced beta-cell apoptosis and impaired glucose-stimulated insulin secretion [24].
  • These results lend direct support to the assumption that sulfonylurea compounds have a substantial extrapancreatic effect on glucose homeostasis, and suggest that this effect contributes to the therapeutic efficacy of these drugs [25].

Anatomical context of aminocarbonylsulfamoylurea


Associations of aminocarbonylsulfamoylurea with other chemical compounds


Gene context of aminocarbonylsulfamoylurea

  • Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity [36].
  • Insulin treatment of ketotic diabetes resulted in a rapid increase in the activity of LPL and decrease in serum triglycerdie level, whereas sulfonylurea treatment of non-insulin-requiring diabetics did not significantly influence the enzyme activity [37].
  • Rifampicin also induces CYP2C-mediated metabolism and thus reduces the plasma concentrations of, for example, the CYP2C9 substrate (S)-warfarin and the sulfonylurea antidiabetic drugs [38].
  • The results indicate direct actions of K(ATP) channel modulators within hair follicles via two types of channels, with SUR 1 and SUR 2, probably SUR2B, sulfonylurea receptors [39].
  • Here, the interaction of HMR 1883 with sulfonylurea receptor (SUR) subtypes and recombinant K(ATP) channels is compared with that of the standard sulfonylurea, glibenclamide, in radioligand receptor binding and electrophysiological experiments [40].

Analytical, diagnostic and therapeutic context of aminocarbonylsulfamoylurea


  1. A comparison of glyburide and insulin in women with gestational diabetes mellitus. Langer, O., Conway, D.L., Berkus, M.D., Xenakis, E.M., Gonzales, O. N. Engl. J. Med. (2000) [Pubmed]
  2. Potentiation of hypoglycemic effect of sulfonylureas by halofenate. Jain, A.K., Ryan, J.R., McMahon, F.G. N. Engl. J. Med. (1975) [Pubmed]
  3. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R. JAMA (1999) [Pubmed]
  4. Effects of sulfonylureas on the synthesis and secretion of plasminogen activator from bovine aortic endothelial cells. Kuo, B.S., Korner, G., Bjornsson, T.D. J. Clin. Invest. (1988) [Pubmed]
  5. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. Landry, D.W., Oliver, J.A. J. Clin. Invest. (1992) [Pubmed]
  6. Capillary electrophoretic detection of metabolites in the urine of patients receiving hypoglycemic drug therapy. Roche, M.E., Oda, R.P., Lawson, G.M., Landers, J.P. Electrophoresis (1997) [Pubmed]
  7. Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease. Holemans, S., Javoy-Agid, F., Agid, Y., De Paermentier, F., Laterre, E.C., Maloteaux, J.M. Brain Res. (1994) [Pubmed]
  8. Stroke: cardiovascular risk factors and the quantitative effects of dietary treatment on them. Altmann, J., Kornhuber, A.W., Kornhuber, H.H. Eur. Neurol. (1987) [Pubmed]
  9. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Kawai, T., Takei, I., Oguma, Y., Ohashi, N., Tokui, M., Oguchi, S., Katsukawa, F., Hirose, H., Shimada, A., Watanabe, K., Saruta, T. Metab. Clin. Exp. (1999) [Pubmed]
  10. Insulin: either alone or combined with oral hypoglycemic agents. Firth, R.G. Prim. Care (1988) [Pubmed]
  11. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Kojima, H., Fujimiya, M., Matsumura, K., Younan, P., Imaeda, H., Maeda, M., Chan, L. Nat. Med. (2003) [Pubmed]
  12. Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels. Amoroso, S., Schmid-Antomarchi, H., Fosset, M., Lazdunski, M. Science (1990) [Pubmed]
  13. Gap junction development is correlated with insulin content in the pancreatic B cell. Meda, P., Halban, P., Perrelet, A., Renold, A.E., Orci, L. Science (1980) [Pubmed]
  14. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. Hayward, R.A., Manning, W.G., Kaplan, S.H., Wagner, E.H., Greenfield, S. JAMA (1997) [Pubmed]
  15. ATP-sensitive potassium channelopathies: focus on insulin secretion. Ashcroft, F.M. J. Clin. Invest. (2005) [Pubmed]
  16. Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea. Sone, H., Takahashi, A., Yamada, N. Ann. Intern. Med. (2001) [Pubmed]
  17. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Melander, A. Diabetes (2004) [Pubmed]
  18. The sulfonylurea herbicide sulfometuron methyl is an extremely potent and selective inhibitor of acetolactate synthase in Salmonella typhimurium. LaRossa, R.A., Schloss, J.V. J. Biol. Chem. (1984) [Pubmed]
  19. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Kipnes, M.S., Krosnick, A., Rendell, M.S., Egan, J.W., Mathisen, A.L., Schneider, R.L. Am. J. Med. (2001) [Pubmed]
  20. Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Arauz-Pacheco, C., Ramirez, L.C., Rios, J.M., Raskin, P. Am. J. Med. (1990) [Pubmed]
  21. The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein. Barg, S., Renström, E., Berggren, P.O., Bertorello, A., Bokvist, K., Braun, M., Eliasson, L., Holmes, W.E., Köhler, M., Rorsman, P., Thévenod, F. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  22. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proks, P., Antcliff, J.F., Lippiat, J., Gloyn, A.L., Hattersley, A.T., Ashcroft, F.M. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  23. Specificity of photolabeling of beta-cell membrane proteins with an 125I-labeled glyburide analog. Nelson, D.A., Aguilar-Bryan, L., Bryan, J. J. Biol. Chem. (1992) [Pubmed]
  24. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Maedler, K., Størling, J., Sturis, J., Zuellig, R.A., Spinas, G.A., Arkhammar, P.O., Mandrup-Poulsen, T., Donath, M.Y. Diabetes (2004) [Pubmed]
  25. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Greenfield, M.S., Doberne, L., Rosenthal, M., Schulz, B., Widstrom, A., Reaven, G.M. Diabetes (1982) [Pubmed]
  26. A morphological basis for intercellular communication between alpha- and beta-cells in the endocrine pancreas. Orci, L., Malaisse-Lagae, F., Ravazzola, M., Rouiller, D., Renold, A.E., Perrelet, A., Unger, R. J. Clin. Invest. (1975) [Pubmed]
  27. In vitro effects of a sulfonylurea on insulin action in adipocytes. Potentiation of insulin-stimulated hexose transport. Maloff, B.L., Lockwood, D.H. J. Clin. Invest. (1981) [Pubmed]
  28. Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. Prince, M.J., Olefsky, J.M. J. Clin. Invest. (1980) [Pubmed]
  29. Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport. Müller, G., Dearey, E.A., Korndörfer, A., Bandlow, W. J. Cell Biol. (1994) [Pubmed]
  30. Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons. Liss, B., Bruns, R., Roeper, J. EMBO J. (1999) [Pubmed]
  31. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Shank, M.L., Del Prato, S., DeFronzo, R.A. Diabetes (1995) [Pubmed]
  32. Molecular basis of sulfonylurea herbicide inhibition of acetohydroxyacid synthase. Pang, S.S., Guddat, L.W., Duggleby, R.G. J. Biol. Chem. (2003) [Pubmed]
  33. Glucagon response to arginine after treatment of diabetes mellitus. Ohneda, A., Ishii, S., Horigome, K., Yamagata, S. Diabetes (1975) [Pubmed]
  34. Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Taskinen, M.R., Beltz, W.F., Harper, I., Fields, R.M., Schonfeld, G., Grundy, S.M., Howard, B.V. Diabetes (1986) [Pubmed]
  35. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy. Proks, P., Girard, C., Baevre, H., Njølstad, P.R., Ashcroft, F.M. Diabetes (2006) [Pubmed]
  36. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. Fukuen, S., Iwaki, M., Yasui, A., Makishima, M., Matsuda, M., Shimomura, I. J. Biol. Chem. (2005) [Pubmed]
  37. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Nikkilä, E.A., Huttunen, J.K., Ehnholm, C. Diabetes (1977) [Pubmed]
  38. Pharmacokinetic interactions with rifampicin : clinical relevance. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J., Kivistö, K.T. Clinical pharmacokinetics. (2003) [Pubmed]
  39. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. Davies, G.C., Thornton, M.J., Jenner, T.J., Chen, Y.J., Hansen, J.B., Carr, R.D., Randall, V.A. J. Invest. Dermatol. (2005) [Pubmed]
  40. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide. Russ, U., Lange, U., Löffler-Walz, C., Hambrock, A., Quast, U. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  41. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., Heikkilä, M. Ann. Intern. Med. (1999) [Pubmed]
  42. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Cleveland, J.C., Meldrum, D.R., Cain, B.S., Banerjee, A., Harken, A.H. Circulation (1997) [Pubmed]
  43. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Auchampach, J.A., Maruyama, M., Cavero, I., Gross, G.J. Circulation (1992) [Pubmed]
  44. Human alpha-endosulfine, a possible regulator of sulfonylurea-sensitive KATP channel: molecular cloning, expression and biological properties. Heron, L., Virsolvy, A., Peyrollier, K., Gribble, F.M., Le Cam, A., Ashcroft, F.M., Bataille, D. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  45. Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. Banerji, M.A., Chaiken, R.L., Lebovitz, H.E. Diabetes (1996) [Pubmed]
WikiGenes - Universities